Cardiol Therapeutics Inc. Class A Common Shares (CRDL)
CRDL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1702123/000110465924041952/0001104659-24-041952-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2021-12-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | CRDL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001702123 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | ON |
| Canadian listing | TSX: CRDL |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $55K |
| Net income | -$22.2M |
| Operating income | -$27.1M |
| Net margin | -40170.4% |
| Operating margin | -49091.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $58.8M |
| Total assets | $61.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2264.9× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 40-F 2026-03-31 |
| Cash and burn | 21.4M CAD cash; operating cash flow -6.0M CAD a quarter. | Report 2025-12-31 |
| Shares outstanding | 100,257,009 (2025-12-31); 82,608,992 a year earlier; 64,042,536 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO Canada LLP, Oakville, Canada | PCAOB Form AP 2026-04-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -33.8M CAD | -23.9M CAD | 21.4M CAD | No debt tags | Needs four quarters | 40-F 2026-03-31 |
| FY 2024 2024-12-31 | Not filed | -36.7M CAD | -25.1M CAD | 30.6M CAD | No debt tags | Needs four quarters | 40-F 2026-03-31 |
| FY 2023 2023-12-31 | Not filed | -28.1M CAD | -25.2M CAD | 34.9M CAD | No debt tags | Needs four quarters | 40-F 2025-03-31 |
| FY 2022 2022-12-31 | Not filed | -30.9M CAD | -27.2M CAD | 59.5M CAD | No debt tags | Needs four quarters | 20-F 2024-04-01 |
| FY 2021 2021-12-31 | 79K CAD | -31.6M CAD | -23.5M CAD | 83.9M CAD | No debt tags | 79K CAD | 20-F 2024-04-01 |
| FY 2020 2020-12-31 | Not filed | -20.6M CAD | -9.1M CAD | 14.0M CAD | No debt tags | Needs four quarters | 20-F 2023-03-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 40-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 189 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -16.7% |
| 3 months | -41.5% |
| Year to date | +4.8% |
| 1 year | -2.0% |
| From 52-week high | -56.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $1.89 | -21.58% | $126.7M |
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
| CMPX | Compass Therapeutics Inc. | $0.6615 | -14.51% | $119.1M |
| FATE | Fate Therapeutics Inc. | $1.14 | -10.94% | $138.6M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| TARA | Protara Therapeutics Inc. | $2.38 | -5.93% | $146.5M |
| HUMA | Humacyte Inc. | $0.5403 | -3.24% | $150.1M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier